AI assistant
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2026
Jan 6, 2026
31542_dirs_2026-01-06_750288f2-4bf1-4876-ad19-e0e79007895c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2026-01-05
Reporting Person: Kalb Michael Wayne (Executive Vice President & CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-01-05 | Common Stock, par value $0.001 per share | M | 7139 | — | Acquired | 15745 | Direct |
| 2026-01-05 | Common Stock, par value $0.001 per share | F | 2080 | — | Disposed | 13665 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-01-05 | Restricted Stock Units | $ | M | 7139 | Disposed | Common Stock (7139) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock.
F3: Derivative securities vest in equal tranches, 1/5th on January 1, 2025, 1/5th on January 1, 2026, 1/5th on January 1, 2027, 1/5th on January 1, 2028, and 1/5th on January 1, 2029.
F4: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on January 5, 2026.